entity
alzheimer's disease
probably alzheimer's disease
probable alzheimer's disease
probable ad
female must be of non-childbearing potential (i.e. surgically sterilized or at least 2 years post-menopausal)
mild cognitive impairment
dementia
female meets one or more of the following criteria:~post-menopausal females defined as menopause is defined as>6months without menstrual period with an appropriate clinical profile, e.g. age appropriate, history of vasomotor symptoms. however if indicated this should be confirmed by oestradiol and fsh levels consistent with menopause (according to local laboratory ranges).
pre-menopausal females with a documented (medical report verification) hysterectomy and/or bilateral oophorectomy only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
the patient must have successfully completed the full 78-week duration of the double-blind cl-758007 study
reasonably good nutritional status
female subjects must be post-menopausal (i.e. >1 year without menstrual period), surgically sterile, or agree to use adequate method of contraception
pre-menopausal or who have been post-menopausal for <1 year must undertake pregnancy testing (urine test) at visit 1, which must be negative
females must be non-child-bearing potential.
male patients with female partners of child-bearing potential should use effective contraception for the duration of the study.
completed the 12 month visit of 49653/461 (12 months of treatment) without tolerability issues
female subjects must be post-menopausal (i.e. >6 months without menstrual period), surgically sterile, or if of child-bearing potential, using effective contraceptive measures (oral contraceptives, norplant, depo-provera, an intra-uterine device (iud) a diaphragm with spermicide or a condom with spermicide).
not pregnant, planning a pregnancy, or capable of becoming pregnant
probable alzheimer's disease (ad)
mild cognitive impairment (mci) or alzheimer's disease (ad)
female (post-menopausal or surgically sterile
mild to moderate alzheimer's disease who are receiving donepezil
ad
no history or evidence of any other cns disorder that could be interpreted as a cause of dementia
no diagnosis of vascular dementia
no history of significant psychiatric illness such as schizophrenia or bipolar affective disorder
no evidence of the following: current vitamin b12 deficiency, positive syphilis serology, positive hiv test, or abnormalities in thyroid function
no cognitive rehabilitation
no history of drug or alcohol abuse
cardiac history
no history of uncontrolled seizure disorder
no history of malignancy
women cannot be pregnant or breastfeeding
must have been ongoing in trx-014-001 at time of study termination
no history of significant psychiatric illness such as schizophrenia or bipolar affective disorder.
no evidence of the following: current vitamin b12 deficiency, positive syphilis serology, positive hiv test, or abnormalities in thyroid function~no cognitive rehabilitation within 6 months of the study
giving informed consent to lumbar puncture
adequate english literacy to complete neuropsychological testing
generally stable level of health
amnestic mci
no evidence of cognitive impairment by medical history
early stage of ad
maximum of 2 cups of black tea/die
no green tea
not more than > 500 ml/die of grapefruit juice
probable alzheimer´s disease
treated stable hypertension
menopause women
her/his spouse consent with contraception during the study period and 90 days after end of study
amnestic or non-amnestic mild cognitive impairment
moderate alzheimer's disease
hypovitaminosis d (i.e., serum 25-hydroxyvitamin d [25ohd]concentration < 30 ng/ml)
no hypercalcemia (defined as serum calcium concentration ≥ 2,65 mmol/l)
females must be > 2 years post-menopausal or surgically sterile
randomized into study m10-985 and completed dosing through week 24
male, the subject is surgically sterile (vasectomy, is sexually inactive, or is using a barrier method of birth control (condom) with spermicidal foam/gel/film/cream/suppository
postmenopausal for at least 2 years or is surgically sterile
inclusion criteria:~previous participation in study abe4869g or abe4955g and completion of the week 73 visit
male participants with partners with reproductive potential, agreement to use a reliable means of contraception (e.g., condoms)
female participants, a negative pregnancy test
amci
history of academic achievement and/or employment sufficient to exclude mental retardation
membership in psen1 e280a mutation carrier kindred
does not meet criteria for dementia due to ad
does not meet criteria for mild cognitive impairment (mci) due to ad
female, and not documented (by medical records or physician's note) to be surgically sterile (absence of ovaries and/or uterus) or postmenopausal, willing to undergo pregnancy tests at protocol-specific timepoints~for women who are not documented (by medical records or physician's note) to be surgically sterile (absence of ovaries and/or uterus) or postmenopausal, agreement to remain abstinent or use two adequate methods of contraception
men with partners of childbearing potential (that is [i.e.], women who are not surgically sterile and are not postmenopausal), agreement to remain abstinent or use a condom as a method of contraception
mild to moderate probable ad
primary degenerative dementia
females are not of childbearing potential
completed visit 7 (completion visit) in the lead-in double-blind, placebo controlled clinical studies 14861a/nct01955161 or 14862a/nct02006641
completed visit 6 (week 28) of the olex
do not have a history of major depression
subject is not pregnant, lactating, or of childbearing potential (i.e., women must be two years post-menopausal or surgically sterile)
mild alzheimer's disease (ad)
mci due to ad,
dementia due to possible or probable ad
fertile, sexually active subjects (men and women) must use an effective method of contraception
female subjects and the female partner of male subjects must be surgically sterile (hysterectomy or bilateral tubal ligation), postmenopausal for at least 1-year, or willing to practice adequate methods of contraception if of childbearing potential (defined as consistent use of combined effective methods of contraception [including at least 1 barrier method])
completed the pivotal ad-4833/tomm40_301 study with an adjudicated diagnosis of mild cognitive impairment (mci) due to alzheimer's disease (ad) without ongoing serious adverse events (saes) from ad-4833/tomm40_301
mci due to ad
ad dementia
postmenopausal or surgically sterile females only
amnestic and non-amnestic mci
alzheimer's early-stage, sporadic-type
early alzheimer's disease (ad)
mild cognitive impairment (mci) due to probable ad or of mild ad
probable alzheimer's
family history of alzheimer's disease
female patients must be either surgically sterile or at least 2 years postmenopausal
male patients must either be surgically sterile, or he and his female spouse/partner who is of childbearing potential must be using highly effective contraception
early signs of dementia of alzheimer type
mild to moderate alzheimer's disease
women must be neither pregnant nor nursing, and are either surgically sterile, postmenopausal or premenopausal using an acceptable method of contraception.
alzheimer's disease or mild cognitive impairment due to alzheimer's disease
no known allergy or oversensitivity against valaciclovir or aciclovir
mild cognitive impairment (mci) due to alzheimer's disease (ad) or mild ad
amyloid beta positivity
dementia of alzheimer's type
mild cognitive impairment (amnestic or amnestic plus other) with biomarkers that suggest intermediate or high likelihood that the syndrome is due to ad
not pregnant, lactating or of child-bearing potential (women must be >2 years post-menopausal or surgically sterile)
female subject with child-bearing potential agrees to take reliable contraceptive method during the participation of the study (females with no child-bearing potential have to be surgically sterilized or at least 2 years after post-menopausal)
dementia due to possible or probable alzheimer's disease
female, postmenopausal
non-smoker
probable alzheimer's dementia
no active history of suicide attempt
more than 1 lifetime suicide attempt
mild ad
mild to moderate alzheimer's type dementia
mci or dementia due to ad
completion of participation in the anavex2-73-ad-004 double-blind study
suicidal behavior
if of childbearing potential is not pregnant through urine pregnancy testing
mild-to-moderate ad dementia
dementia, due probably to ad
mild to moderate ad
probable alzheimer dementia
probable alzheimer's disease (ad) dementia
prodromal ad
women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods
mci or ad
probable mild to moderate ad dementia
probable ad dementia
mild ad or moderate ad
gradual and progressive change in memory function
mild cognitive impairment or mild dementia due to either: parkinson's disease associated with rem sleep behavior disorder (rbd+pd) and positive response to the rbd single-question screen (rbd1q) and without hallucinations; or alzheimer's disease (ad)
females of childbearing potential (i.e., not postmenopausal or surgically sterile) who have a male partner must have a negative serum pregnancy test result and must agree to one of the following from start of screening through 30 days after the last study medication administration: use a highly effective method of birth control; or monogamous relationship with a male partner of confirmed sterility; or practice complete abstinence.
of non-childbearing potential may be enrolled if it is documented that they are postmenopausal
mild cognitive impairment (mci)
subjects who can walk with or without assist device
women not of childbearing potential (wnocbp) may participate
completed lead-in protocol tb006ad2102 (participants from both study drug and placebo groups) or are eligible for the lead-in study but were not enrolled (de novo)
contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
females must be of non-childbearing potential
ambulatory
mild cognitive impairment or mild dementia
completed rethink-alz (pti-125-07) or refocus-alz (pti-125-06)
female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly)
*non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start
male participants must be sterile or sexually inactive or agree not to father a child
no evidence of current suicidal ideation or previous suicide attempt in the past 2 months as evaluated in the columbia suicide severity rating scale nor suicidal behavior
good general health
completion of the planned treatment period in the al002-2 study
good work history sufficient to exclude mental retardation
preserved activities of daily living
alternative causes of cognitive decline are ruled out
no contraindications to the mri
